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RET (rearranged during transfection) is a receptor
tyrosine kinase overexpressed in a subset of oestrogen
receptor (ER)-positive breast cancers whose expression
is regulated by ER signalling. The article from the
Hynes group has reported for the first time that RET
expression can also be regulated by the inflammatory
cytokine IL-6. Importantly, RET and IL-6 interact at a
functional level to control migration and the metastatic
potential of ER-positive breast cancer cells, in a
process that is mediated by FAK activation. Further,
targeting RET with receptor tyrosine kinase inhibitors
was reported to be more effective than endocrine
therapies in impairing metastatic dissemination
in vivo, thereby indicating a level of RET regulation
that is independent of ER.block primary tumour growth of ER-positive breast can-Background
Many breast cancers are characterised by amplification
or overexpression of receptor tyrosine kinases such as
ErbB2/human epidermal growth factor receptor 2
(HER2), epidermal growth factor receptor, insulin-like
growth factor receptor and fibroblast growth factor re-
ceptor 1 that can drive tumour growth. Targeting
ErbB2/HER2 with the specific antibody trastuzumab
has changed the standard of treatment and has im-
proved prognosis for ErbB2/HER2-positive breast can-
cer patients. However, as ErbB2/HER2-positive breast
cancers represent approximately 25% of all breast can-
cer cases, there is a need to identify additional kinases
that can acquire driver characteristics in breast cancer
progression and impact on therapy response.
An increasing body of evidence has now documented
that the receptor tyrosine kinase RET is overexpressed
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2014cancers that depend on oestrogens for their growth and
survival [1-3]. Targeting ER function with endocrine
therapy is the most common and effective treatment for
this subset of breast cancers, but recent data have
shown that RET signalling, driven by its ligand GDNF,
has a negative impact on the response of ER-positive
breast cancer cells to aromatase inhibitors [4] and tam-
oxifen [5,6].The article
The work recently published from the Hynes laboratory
has uncovered a novel role for RET in migration and me-
tastasis, in addition to confirming the relevance of RET in
controlling proliferation and growth of ER-positive breast
cancer [7]. Importantly, using in vivo models they demon-
strate that tyrosine kinase inhibitors which target RET can
cers with an efficiency that is comparable with endocrine
agents, the current standard of care for this subset of tu-
mours. In contrast, the authors show that RET inhibition
is more effective than endocrine agents (that is, fulvestrant
and tamoxifen) in preventing metastatic dissemination.
Using a multidisciplinary approach, they demonstrate that
targeting RET and/or ER signalling impacts on the inflam-
matory response. In particular, they reveal a feed-forward
RET–IL-6 loop in which RET activation increases IL-6
levels that in turn induce RET expression. Furthermore,
IL-6 signalling can be blocked by RET inhibition and
RET-mediated cell migration can be attenuated by an IL-6
blocking antibody. The functional link between RET and
IL-6 comes from a reverse protein array analysis on xeno-
graft samples, which revealed that RET inhibition results
in phospho-FAK, phospho-STAT3 and phospho-AKT re-
duction. From this observation, FAK was demonstrated to
act as intracellular integrator of RET–IL-6 signalling, with
FAK activity being essential for both IL-6-mediated and
RET-mediated cell migration (Figure 1).Central Ltd. The licensee has exclusive rights to distribute this article, in any
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Figure 1 RET–IL-6 interaction mediates breast cancer cell motility. (A) GDNF binds to GFRα1 and induces RET activation. IL-6-mediated IL-6
receptor (IL6R) activation leads to co-receptor gp130 phosphorylation (P). (B) RET directly interacts with and activates FAK, while IL6R/gp130
activation induces JAK phosphorylation. Data presented by Gattelli and colleagues suggest a transient interaction between the IL6R:JAK and RET:
FAK activated complexes that form in response to IL-6 and GDNF treatment, respectively [7]. (C) RET and FAK are essential to IL-6:JAK-mediated
STAT3 activation underpinning the observed requirement for RET in IL-6-stimulated breast cancer cell migration and invasion.
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The novel findings of this article are that RET inhibition
impacts not only on primary tumour growth of ER-
positive breast cancers but also on their metastatic dis-
semination, and that the promotion of migration and
metastasis of ER-positive breast cancer cells promoted
by IL-6 and RET signalling is mediated by FAK activity
(Figure 1).
The implications of this study are multiple. Inflamma-
tory response pathways were previously reported to be
regulated by GDNF-mediated RET activation. Particularly,
a GDNF–RET set of genes associated with poor prognosis
and endocrine therapy resistance was largely populated by
interferon-related genes [4]. Gattelli and colleagues for the
first time highlight the functional interconnection betweenRET downstream signalling and inflammatory response in
an endocrine therapy setting [7]. Moreover, although RET
has been shown to be an ER-dependent gene [2], this
current study additionally shows that IL-6 can induce
RET expression. The importance of this observation is
that fulvestrant administration, which degrades ER and
thereby disrupts ER signalling, would be expected to nega-
tively impact on RET expression. Instead, Gattelli and col-
leagues show that fulvestrant induces cancer cells to
produce IL-6, resulting in increased RET expression and
thus creating a feed-forward RET–IL-6 expression loop.
This novel observation needs to be considered to com-
pletely understand the role of RET in breast cancer.
To date, most of the mechanistic insights into RET have
been described in the ER-positive breast cancer subset.
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and colleagues’ article is that the clinical information is
based on a cohort of patients enriched for ER-negative tu-
mours (52/89, 58.4%). Particularly, approximately 70% of
the triple-negative breast cancers analysed show a high
RET expression. This observation raises the intriguing
question of whether an inflammatory regulation of RET
expression (for example, via IL-6 signalling) could drive
ER-independent RET expression. In addition, the tumour
microenvironment may contribute to potentiate RET acti-
vation and signalling. Proinflammatory cytokines were
reported previously to induce the expression of the RET
ligand GDNF [1]. In addition, cancer-associated fibro-
blasts mediate tumour-enhancing inflammation and
produce IL-6 [8]. Consequently, given the current report
that IL-6 promotes RET expression, the role of the
GDNF–RET axis may be more relevant in those cancers
characterised by an inflammatory response and an acti-
vated tumour microenvironment.
The second important finding of this current article is
that RET and IL-6 are also connected at a functional level.
Previous reports state that RET binds to the FERM do-
main of FAK, an interaction that results in transactivation
of both proteins [9], and that RET is degraded by autoph-
agy in cancer cells with altered/reduced FAK signalling,
preventing RET binding to FAK at focal adhesions [10].
The novelty of Gattelli and colleagues’ article is that it
demonstrates FAK is essential for IL-6-mediated RET-
dependent cell migration. Both RET and FAK inhibition
impaired IL-6-induced migration and metastatic ability
of breast cancer cells, and, conversely, when FAK is
inhibited, RET-induced and IL-6-induced migration is
abolished.
These findings together have the intriguing thera-
peutic possibility of targeting FAK as a key signalling
pathway downstream of RET to block tumour growth
and metastatic potential not only in ER-positive breast
cancers but also, potentially, in other breast cancer sub-
types. This hypothesis may be an important strategy in
tumours where an inflammatory response could in-
crease the expression of the molecular players involved
in RET–IL-6 crosstalk.
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